Plus Therapeutics Stock Today
PSTV Stock | USD 1.75 0.01 0.57% |
Performance0 of 100
| Odds Of DistressOver 82
|
Plus Therapeutics is selling for under 1.75 as of the 17th of April 2024; that is 0.57 percent increase since the beginning of the trading day. The stock's lowest day price was 1.74. Plus Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Plus Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 18th of March 2024 and ending today, the 17th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of November 2000 | Category Healthcare | Classification Health Care |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. The company has 4.35 M outstanding shares of which 46.76 K shares are at this time shorted by private and institutional investors with about 1.14 trading days to cover. More on Plus Therapeutics
Moving together with Plus Stock
0.64 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
Moving against Plus Stock
0.77 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
0.62 | RZLT | Rezolute Trending | PairCorr |
0.56 | CELC | Celcuity LLC Financial Report 20th of May 2024 | PairCorr |
0.52 | BMY | Bristol Myers Squibb Financial Report 25th of April 2024 | PairCorr |
0.48 | ABBV | AbbVie Inc Financial Report 25th of April 2024 | PairCorr |
0.46 | CCCC | C4 TherapeuticsInc Financial Report 2nd of May 2024 | PairCorr |
0.44 | ERAS | Erasca Inc Financial Report 20th of May 2024 | PairCorr |
Plus Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Plus Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Plus Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO President | MD MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation Analysts covering Plus Therapeutics report their recommendations after researching Plus Therapeutics' financial statements, talking to executives and customers, or listening in on Plus Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Plus Therapeutics. The Plus consensus assessment is calculated by taking the average forecast from all of the analysts covering Plus Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength Based on the key indicators related to Plus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Plus Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Plus Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plus Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Plus Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Plus Therapeutics' financial leverage. It provides some insight into what part of Plus Therapeutics' total assets is financed by creditors.
|
Plus Therapeutics (PSTV) is traded on NASDAQ Exchange in USA. It is located in 4200 Marathon Boulevard, Austin, TX, United States, 78756 and employs 20 people. Plus Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.62 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Plus Therapeutics's market, we take the total number of its shares issued and multiply it by Plus Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Plus Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.35 M outstanding shares of which 46.76 K shares are at this time shorted by private and institutional investors with about 1.14 trading days to cover.
Plus Therapeutics currently holds about 20.27 M in cash with (12.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6.
Check Plus Therapeutics Probability Of Bankruptcy
Ownership AllocationRoughly 95.0 pct. of Plus Therapeutics outstanding shares are held by general public with 1.45 % owned by insiders and only 3.27 (%) by third-party entities.
Check Plus Ownership Details
Plus Stock Price Odds Analysis
Depending on a normal probability distribution, the odds of Plus Therapeutics jumping above the current price in 90 days from now is about 91.69%. The Plus Therapeutics probability density function shows the probability of Plus Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Plus Therapeutics has a beta of 0.732 indicating as returns on the market go up, Plus Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Plus Therapeutics will be expected to be much smaller as well. Additionally, plus Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Plus Therapeutics to move above the current price in 90 days from now is about 91.69 (This Plus Therapeutics probability density function shows the probability of Plus Stock to fall within a particular range of prices over 90 days) .
Plus Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Plus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Plus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Plus Therapeutics' value.Instituion | Recorded On | Shares | |
Jpmorgan Chase & Co | 2023-09-30 | 2.0 | |
Group One Trading, Lp | 2023-09-30 | 1.0 | |
Renaissance Technologies Corp | 2023-12-31 | 33 K | |
Geode Capital Management, Llc | 2023-09-30 | 26.5 K | |
Millennium Management Llc | 2023-09-30 | 19.7 K | |
Vanguard Group Inc | 2023-09-30 | 16.2 K | |
Hrt Financial Llc | 2023-09-30 | 11.2 K | |
Blackrock Inc | 2023-12-31 | 7 K | |
Ubs Group Ag | 2023-09-30 | 5.1 K | |
Tower Research Capital Llc | 2023-09-30 | 1.5 K | |
Citigroup Inc | 2023-09-30 | 579 |
Plus Therapeutics Historical Income Statement
Plus Therapeutics Income Statement is one of the three primary financial statements used for reporting Plus's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Plus Therapeutics revenue and expense. Plus Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Plus Therapeutics' Reconciled Depreciation is fairly stable compared to the past year. View More FundamentalsPlus Stock Against Markets
Picking the right benchmark for Plus Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Plus Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Plus Therapeutics is critical whether you are bullish or bearish towards Plus Therapeutics at a given time. Please also check how Plus Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Plus Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
All Next | Launch Module |
Plus Therapeutics Corporate Executives
Elected by the shareholders, the Plus Therapeutics' board of directors comprises two types of representatives: Plus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Plus. The board's role is to monitor Plus Therapeutics' management team and ensure that shareholders' interests are well served. Plus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Plus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew CPA | VP CFO | Profile |
How to buy Plus Stock?
Before investing in Plus Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Plus Therapeutics. To buy Plus Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Plus Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Plus Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Plus Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Plus Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Plus Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.
Already Invested in Plus Therapeutics?
The danger of trading Plus Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Plus Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Plus Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Plus Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Plus Therapeutics is a strong investment it is important to analyze Plus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Plus Therapeutics' future performance. For an informed investment choice regarding Plus Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Plus Stock analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
CEOs Directory Screen CEOs from public companies around the world | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Plus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Plus Therapeutics. If investors know Plus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Plus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.24) | Revenue Per Share 1.564 | Quarterly Revenue Growth 7.695 | Return On Assets (0.47) | Return On Equity (5.22) |
The market value of Plus Therapeutics is measured differently than its book value, which is the value of Plus that is recorded on the company's balance sheet. Investors also form their own opinion of Plus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Plus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Plus Therapeutics' market value can be influenced by many factors that don't directly affect Plus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Plus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Plus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Plus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.